These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19055896)

  • 1. [Impact of the spanish pharmacovigilance system recommendations on the publication of cases of adverse drug reaction].
    Esteban Calvo C; Ibáñez Ruiz C; Salgueiro Vázquez E; Manso Rodríguez G
    Aten Primaria; 2008 Nov; 40(11):555-8. PubMed ID: 19055896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database.
    Impicciatore P; Mucci M
    Drug Saf; 2010 Sep; 33(9):765-73. PubMed ID: 20701409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for submitting adverse event reports for publication.
    Kelly WN; Arellano FM; Barnes J; Bergman U; Edwards IR; Fernandez AM; Freedman SB; Goldsmith DI; Huang K; Jones JK; McLeay R; Moore N; Stather RH; Trenque T; Troutman WG; van Puijenbroek E; Williams F; Wise RP; ;
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):581-7. PubMed ID: 17471601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for submitting adverse event reports for publication.
    Kelly W; Arellano F; Barnes J; Bergman U; Edwards R; Fernandez A; Freedman S; Goldsmith D; Huang K; Jones J; McLeay R; Moore N; Stather R; Trenque T; Troutman W; van Puijenbroek E; Williams F; Wise R; ;
    Therapie; 2009; 64(4):289-94. PubMed ID: 19804709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain-differences between regional pharmacovigilance centres and pharmaceutical industry.
    Fernandez-Fernandez C; Lázaro-Bengoa E; Fernández-Antón E; Quiroga-González L; Montero Corominas D
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1175-1181. PubMed ID: 32447435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for submitting adverse event reports for publication.
    Kelly WN; Arellano FM; Barnes J; Bergman U; Edwards RI; Fernandez AM; Freedman SB; Goldsmith DI; Huang KA; Jones JK; McLeay R; Moore N; Stather RH; Trenque T; Troutman WG; van Puijenbroek E; Williams F; Wise RP; ;
    Drug Saf; 2007; 30(5):367-73. PubMed ID: 17472416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.
    Bennett CL; Schooley B; Taylor MA; Witherspoon BJ; Godwin A; Vemula J; Ausdenmoore HC; Sartor O; Yang YT; Armitage JO; Hrushesky WJ; Restaino J; Thomsen HS; Yarnold PR; Young T; Knopf KB; Chen B
    PLoS One; 2019; 14(7):e0219521. PubMed ID: 31365527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality criteria for early signals of possible adverse drug reactions.
    Edwards IR; Lindquist M; Wiholm BE; Napke E
    Lancet; 1990 Jul; 336(8708):156-8. PubMed ID: 1973481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].
    Auriche M; Bertrand P; Blay N; Danan G; Hamel JD; Imbs JL; Lagier G; Micaleff A; Moore N; Ollagnier M; Reveilleau-Richard S; Soubrié C; Weber F
    Therapie; 1997; 52(2):123-7. PubMed ID: 9231506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality of the publication of adverse drug reactions in the letters to the editor section of four Spanish internal medicine and general medicine journals].
    Sempere E; Palop V; Bayón A; Sorando R; Martínez-Mir I
    Aten Primaria; 2006 Mar; 37(4):187-92; discussion 193-4. PubMed ID: 16545261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
    Aronson JK
    Drug Saf; 2008; 31(4):355-6; author reply 356-7. PubMed ID: 18366246
    [No Abstract]   [Full Text] [Related]  

  • 14. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems.
    Carvajal A; Macias D; Sáinz M; Ortega S; Martín Arias LH; Velasco A; Bagheri H; Lapeyre-Mestre M; Montastruc JL
    Drug Saf; 2006; 29(2):143-9. PubMed ID: 16454541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dronedarone and renal impairment: evaluation of Spanish postmarketing reports and review of literature.
    Tarapués M; Cereza G; Figueras A
    Expert Opin Drug Saf; 2015 Jun; 14(6):807-13. PubMed ID: 25967281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.